Survey data consistently shows that patients in Lithuania are more satisfied with services than a few years ago. For instance, according to Eurobarometer, the population’s view on the quality of health care improved dramatically between 2009 and 2013. Between these 4 years, the share of Lithuanians rating the overall quality of health care in the country as good increased from 40 to 65%, the largest increase among European Union countries, although this share is still below the EU average (71%). However, measures of clinical outcomes show that progress is required at all levels.
Prevention and treatment at the primary care level can still improve. For instance, immunisation rates could be higher. High rates of children immunisation were one of the hallmarks of soviet systems, which many countries have retained. Results in this regard in Lithuania are a bit disappointing being around or slightly below OECD averages. Although Influenza vaccination coverage for people above 65 is much higher than in Latvia and Estonia, at 19.5% it also remains well below the OECD average of 43% in 2015.
PHC in Lithuania is increasingly effective in managing chronic diseases and keeping people out of the hospital. Hospitalisations for ambulatory care sensitive conditions are among the key quality indicators for primary care. Hospitalisations for these conditions have been declining in Lithuania since 2005, although from very high starting levels. In fact, for Asthma and COPD, the rates are converging with OECD averages. However, this progress is only relative as many countries manage to achieve substantially lower rates of hospitalisations. On the other hand, despite progress, for congestive heart failure, the proportion of patients hospitalised still remains the highest among 32 countries reporting this indicator to the OECD, more than twice the average rate. Hospitalisation rates for diabetes are a third higher than the OECD average and do not seem to decline.
Hospital mortality for acute conditions is also stubbornly high. Mortality after hospitalisation for acute conditions is the most common indicator for measuring hospital care quality and is collected by the OECD for international comparison purposes. For the first time, Lithuania provided 30 day mortality data for acute myocardial infarction, haemorrhagic stroke and ischemic stroke in 2017. In all cases, Lithuania’s figures considerably exceed OECD averages. For instance, Lithuania has the second highest mortality rates compared to OECD countries that are able to link mortality data across health providers for AMI and ischaemic stroke. Although Lithuanian data is only available for four years (2012–2015), results have not improved over this period. This reinforces the recommendation to monitor the impact of on-going clustering of stroke and cardiac services. In addition, Lithuania should expand the number of quality indicators reported to the OECD, particularly on patient safety to better benchmark its performance.
Cancer offers a disease-oriented and systemic perspective on quality as results depend on both effective PHC and hospital services. Despite progress, PHC providers struggle to ensure better coverage of cancer screening. Lithuania has set up publicly funded population-based screening programs for common cancers: breast, prostate, colorectal and cervical cancer and coverage of the target population has increased over the last 10 years. For instance, in 2015, 45% of targeted women had been screened for breast cancer compared to only 12% in 2006, a significant improvement from very low levels but still below the OECD average of 61%.
Overall, the effectiveness of cancer care quality has improved considerably but still lags behind most OECD countries. Five-year survival rates after cancer diagnosis for most forms of cancer have increased substantially over the past decade and faster than in many other countries, but remain among the lowest in the OECD. Breast cancer survival has increased from 65% to 74% between 2000–04 to 2010–14, but it remains behind those of neighbouring Baltic countries Latvia and Estonia. Similarly colorectal cancer treatment is increasingly successful and at par with neighbouring countries. Colon cancer survival has increased from 45% to 57% in the same time period (CONCORD programme, LSHTM, 2018). For prostate cancer, survival has doubled between the late 1990s and the late 2000s. However, much of the increase in cancer survival is driven by earlier detection, which increases survival also without decreasing mortality (Krilaviciute et al., 2014). All in all thus, from diagnostic to treatment, progress is still needed.
To summarise, there remains room to improve the efficiency and quality in the Lithuanian health system. Progress in restructuring the hospital sector has been slower than in other countries and many facilities still perform very few surgeries and deliveries, which is inefficient but also detrimental to quality and carries a risk for patients. The ongoing initiatives to cluster services in fewer hospitals, and develop a small number of specialised hospitals for some conditions, are promising but need to be extended, sustained over a long time frame and their impact evaluated.
PHC is well organised and reflects best OECD practices and several indicators suggest that PHC has a positive impact on wider system efficiency, as shown by the decreasing hospitalisations for ambulatory care sensitive conditions. However, the coverage of preventive services, in particular cancer screening, is still disappointing. Coordination with public health and mental health services has been on the agenda for some time but results are still modest. Curbing unhealthy behaviours, such as harmful drinking and smoking, particularly among men, is essential to closing the gap with high performing OECD countries.
Overall, the focus on quality needs to be strengthened in Lithuania. The quality assurance culture remains underdeveloped and the policies to change this have not yet been effective. Measuring results and holding stakeholders more explicitly accountable for results can contribute to strengthening clinical outcomes.